Significance of Atypical Small Acinar Proliferation and High-Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsy by Koca, Orhan et al.
Korean Journal of Urology
Ⓒ The Korean Urological Association, 2011 736 Korean J Urol 2011;52:736-740
www.kjurology.org
http://dx.doi.org/10.4111/kju.2011.52.11.736
Urological Oncology
Significance of Atypical Small Acinar Proliferation and High-Grade 
Prostatic Intraepithelial Neoplasia in Prostate Biopsy
Orhan Koca, Selahattin Çalışkan, Metin İshak Öztürk, Mustafa Güneş, M. Ihsan Karaman 
Department of Urology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
Purpose: In clinical practice, atypical small acinar proliferation (ASAP) and high-grade 
prostatic intraepithelial neoplasia (HGPIN) are two common findings on prostate 
biopsies. Knowing the frequency of a prostate cancer diagnosis on repeat biopsies would 
aid primary treating physicians regarding their decisions in suspicious cases.
Materials and Methods: One hundred forty-three patients in whom biopsies revealed 
ASAP or HGPIN or both were enrolled in the present study; prostate cancer was not 
reported in the biopsy specimens and at least one repeat biopsy was performed. Age, 
digital rectal examination findings, prostate volumes, and free and total prostate-spe-
cific antigen (PSA) levels and the biopsy results of the patients were recorded.
Results: Of the 97 patients with ASAP on the first set of biopsies, prostate cancer was 
diagnosed in the second and third biopsies of 32 and 6 patients, respectively. Prostate 
cancer was not detected in the second or third biopsies of the 40 patients with HGPIN 
in the first biopsy. Of the 6 patients with ASAP+HGPIN in the first biopsy, prostate 
cancer was detected in 3 patients in the second biopsy and in 1 patient in the third biopsy.
Conclusions: The diagnosis of ASAP is a strong risk factor for prostate cancer. A repeat 
biopsy should be performed for the entire prostate subsequent to the diagnosis of ASAP. 
In patients with HGPIN according to the biopsy result, the clinical decision should be 
based on other parameters, such as PSA values and rectal examination, and a repeat 
biopsy should be avoided if the initial biopsy was performed with multiple sampling.
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INTRODUCTION
Prostate cancer is one of the most prevalent types of cancer 
in men, and transrectal ultrasound (TRUS)-guided pros-
tate biopsy, a reliable and easy-to-perform method, is ac-
cepted as the gold standard in the diagnosis of this disease. 
The use of prostate-specific antigen (PSA) in clinical prac-
tice has led to an increase in the prevalence of prostate can-
cer [1]. Elevated serum PSA levels or suspected prostate 
cancer on the rectal examination require prostate biopsy. 
In patients with negative initial biopsy results, the cancer 
detection rate on repeat biopsy varies between 10% and 
20% [2].
Some small foci of atypical glands with some features of 
adenocarcinoma are found in 1.5% to 9% of prostate biopsy 
specimens. This is referred to as atypical small acinar pro-
liferation (ASAP). ASAP, which is defined as a “focus of 
small acinar structures formed by atypical epithelial cells,” 
is a condition in which the pathologist has insufficient data 
to make a diagnosis and thus raises the suspicion of cancer. 
It has been reported that the cancer detection rate varies 
between 21% and 51% on the second biopsy in patients with 
ASAP [3,4].
Prostatic intraepithelial neoplasia (PIN) is defined as 
“premalignant proliferation of atypical ductal and acinar 
cells.” High-grade prostatic intraepithelial neoplasia 
(HGPIN) is reported in 5% to 7% of prostate biopsies. The 
risk of subsequent cancer varies between 25% and 79% [3]. 
Because the sextant biopsy technique has been increas-
ingly replaced by multiple sampling methods, cancer de-Korean J Urol 2011;52:736-740
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TABLE 1. Characteristics of the 2,433 patients
Age (yr) PSA (ng/ml) f/t PSA ratio PV (cc)
Normal prostates and/or BPH (n=1,513, 62.2%)
Prostate cancer (n=742, 30.5%)
ASAP-HGPIN (n=178, 7.3%)
66.30±9.36
70.24±8.72
69.35±9.79
8.80±7.22
25.69±31.11
  8.75±11.20
0.24±0.08
0.15±0.06
0.24±0.78
66.37±36.68
54.70±33.39
63.10±31.20
PSA: prostate-specific antigen, f/t PSA: free/total prostate-specific antigen, PV: prostate volume, BPH: benign prostatic hyperplasia, 
ASAP: atypical small acinar proliferation, HGPIN: high-grade prostatic intraepithelial neoplasia
tection rates on repeat biopsies following HGPIN have 
declined.
In clinical practice, ASAP and HGPIN are two common 
findings observed on prostate biopsies. Knowing the rate 
of prostate cancer diagnosis on repeat biopsies would aid 
primary treating physicians in the decision-making proc-
ess for suspicious cases. For this purpose, we examined the 
repeat biopsy results of patients with ASAP and HGPIN.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 2,433 
patients who had undergone TRUS-guided prostate biopsy 
for the diagnosis of prostate cancer between 2003 and 2009 
at our hospital. The biopsy results of the patients were clas-
sified into four categories: prostate cancer, normal pros-
tates or benign prostatic hyperplasia (BPH), ASAP, and 
HGPIN.
In the present study, 143 patients with ASAP or HGPIN 
whose biopsy specimens had not revealed prostate cancer 
and who had undergone at least one repeat biopsy were 
enrolled. Age, digital rectal examination (DRE) findings, 
prostate volumes (PV), free and total PSA levels, and the 
biopsy results of the patients were recorded.
The tissue samples were stained with racemase 
(AMACR), p63, and high-molecular weight cytokeratin 
(clone 34βE12) in foci suspicious of cancer (ASAP) in an ef-
fort to make a definitive diagnosis of adenocarcinoma.
The patients in whom repeat biopsies had not been per-
formed for any reason or those having ＜8 quadrant and ex-
tended initial biopsies were excluded from the study. 
Specimens in which transition zone sampling was per-
formed were also excluded. Specimens from 8-12 quadrant 
(mean, 10.8±1.8) biopsies were studied.
The characteristics of patients with ASAP and HGPIN 
on the initial biopsy were compared. The levels of PSA and 
free PSA, PVs, and DRE findings of the patients with 
ASAP/HGPIN on the initial biopsy were compared with re-
spect to the presence of cancer. The Pearson’s chi-square 
test was used to analyze differences in the cancer develop-
ment rate for ASAP and HGPIN. The significance level was 
considered as p＜0.05.
RESULTS
After the initial biopsy, prostate cancer was diagnosed in 
742 of 2,433 patients (30.5%) and normal prostates or BPH 
was reported in 1,513 patients (62.2%). ASAP was found 
in 114 patients (4.7%), HGPIN in 58 patients (2.4%), and 
ASAP+HGPIN in 6 patients (0.2%) (Table 1). One hundred 
forty-three patients in whom repeat biopsy results were 
available were included in the study. The mean age of the 
143 patients was 68.05±8.79 years. Of these patients, the 
mean PSA was 11.33±10.9 ng/ml, the mean free/total PSA 
ratio was 0.31±0.73, and the mean prostate volume was 
60.2±32.4 cc. In 21 patients, DRE findings were found to 
be significant regarding the presence of cancer (Table 2). 
Age, PV, and PSA values did not show any statistically sig-
nificant differences when patients reported as having 
ASAP and those reported as having HGPIN were compared 
(p＞0.05), whereas abnormal DRE findings were sig-
nificantly higher in the ASAP group. 
Of the 143 patients, ASAP, HGPIN, and ASAP+HGPIN 
were detected in 97, 40, and 6 patients, respectively, in the 
initial biopsies. Although second biopsies were performed 
in all patients, third biopsies were performed in only 27 pa-
tients with ASAP and 9 patients with HGPIN.
Of the 97 patients with ASAP, prostate cancer was de-
tected in the second and third biopsies of 32 and 6 patients, 
respectively. The Gleason score was found to be 6 in 26 pa-
tients and 7 in 6 patients who were diagnosed as having 
prostate cancer after the second biopsy. All the patients 
who were diagnosed as having prostate cancer after the 
third biopsy had a Gleason score of 6. The total number of 
patients diagnosed as having prostate cancer was 38, and 
22 of them had T1c tumors, whereas 16 had T2a. None of 
the 40 patients with HGPIN had evidence of prostate can-
cer in the second or third biopsy. Of the 6 patients with 
ASAP+HGPIN, prostate cancer was detected in 3 patients 
in the second biopsy and in 1 patient in the third biopsy 
(Table 3). Furthermore, on repeat biopsies, ASAP and 
HGPIN were detected in 12 and 5 patients, respectively.
DISCUSSION
The incidence of prostate cancer increases with age, and it 
ranks second to lung cancer in terms of incidence and mor-
tality risk [5]. Significant advances have been achieved in 
the diagnosis and treatment of prostate cancer with the in-
troduction of PSA and prostate biopsy techniques. Howev-
er, the histological diagnosis of prostate cancer in biopsy 
specimens remains a challenge for pathologists. A lack of 
availability of immunohistochemical staining, which may 
differentiate benign from malignant acini, and the poor di-Korean J Urol 2011;52:736-740
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TABLE 2. Comparison of the patients with ASAP, HGPIN, and ASAP+HGPIN regarding the presence of prostate cancer
PV (cc) T-PSA (ng/ml) f/t-PSA
Significant 
finding on DRE
ASAP
    Prostate cancer (+)
    Prostate cancer (-)
    p
    Total
52.17±33.9
  65.4±38.1
0.041
  59.9±36.4
7.7±4.2
13.4±18.2
0.032
11.4±15.1
0.17±0.08
0.44±0.13
0.017
0.35±0.15
13
4
0.023
17
HGPIN
    Prostate cancer (+)
    Prostate cancer (-)
    p-value
a
    Total
-
  63.5±44.1
-
  63.5±44.1
-
11.9±7.3
-
11.9±7.3
-
0.23±0.1
-
0.23±0.1
-
1
-
1
ASAP + HGPIN
    Prostate cancer (+)
    Prostate cancer (-)
    p-value
b
    Total
41.2±8.7
47.5±9.9
-
43.3±9.3
7.1±4.2
5.3±4.9
-
6.5±6.9
0.17±0.07
0.29±0.13
-
0.21±0.09
3
0
-
3
ASAP: atypical small acinar proliferation, DRE: digital rectal examination, f/t-PSA: free/total prostate-specific antigen, HGPIN: 
high-grade prostatic intraepithelial neoplasia, PV: prostate volume, T-PSA: total prostate-specific antigen, 
a: Statistical analysis was 
not performed in the patients with HGPIN in the initial biopsy because prostate cancer was not detected in any of the patients, 
b: 
Statistical analysis was not performed in the patients with ASAP+HGPIN because of the small number of patients
TABLE 3. Second and third biopsies results of 143 patients in the study
Initial biopsies, n=143 (100%) ASAP (n=97) HGPIN (n=40) ASAP+HGPIN (n=6)
Second biopsies (n=143, 100%)
    PC
    Normal prostates and/or BPH
    ASAP
    HGPIN
    nTotal (%)
32/97 (33.0)
55/97 (56.7)
8/97 (8.2)
2/97 (2.1)
       97 (100.0)
0
27/40 (67.5)
-
13/40 (32.5)
       40 (100.0)
3/6 (50.0)
1/6 (16.7)
2/6 (33.3)
-
     6 (100.0)
Time of second biopsies (month)
a 3.9±2.1 3.7±1.8 2.7±0.8
Third biopsies, n=39 (27.3%)
    PC
    Normal prostates and/or BPH
    ASAP
    HGPIN
    nTotal (%)
  6/27 (22.2)
18/27 (66.7)
2/27 (7.4)
1/27 (3.7)
       27 (100.0)
0
5/9 (55.6)
-
4/9 (44.4)
     9 (100.0)
1/3 (33.3)
2/3 (66.7)
-
-
     3 (100.0)
Time of third biopsies (month)
a 8.3±3.4 7.9±2.9 5.8±0.5
Values are presented as number (%), ASAP: atypical small acinar proliferation, BPH: benign prostatic hyperplasia, HGPIN: high-grade 
prostatic intraepithelial neoplasia, PC: prostate cancer, 
a: Time elapsed since the first biopsies
agnostic significance of the absence of basal cells in some 
cases complicate the diagnosis of prostate cancer.
TRUS-guided prostate biopsy, which is a reliable and 
easy-to-perform method, is accepted as the gold standard 
in the diagnosis of prostate cancer [6]. The purpose of the 
biopsy is to determine prostate cancer foci by obtaining a 
sufficient amount of samples at the true location without 
increasing morbidity. In the prostate biopsies performed 
for suspected prostate cancer, positive results confirm the 
diagnosis; however, the suspicion of cancer remains with 
negative results. Moreover, the suspicion of cancer be-
comes more prominent if the results of the biopsy reveal 
ASAP or HGPIN. Cancer detection rates decline after the 
first two biopsies. Keetch et al reported cancer detection 
rates in 4 consecutive biopsies to be 34%, 19%, 8%, and 7%, 
respectively in a group of 1,136 patients with PSA values 
higher than 4 ng/ml [7]. In accordance with the literature, 
in the present study, prostate cancer was detected in 30.5% 
of the biopsies performed after the first biopsy.
PIN is defined as “premalignant proliferation of atypical 
ductal and acinar cells.” Four main patterns of HGPIN 
have been identified as follows: flat, micropapillary, cribri-Korean J Urol 2011;52:736-740
Significance of ASAP and HPIN 739
form, and tufting. However, other unusual histologic types 
of HGPIN, such as foamy gland, signet-ring cells, and muci-
nous have also been reported [8]. Borboroglu et al showed 
a 4% HPIN rate in extensive repeat biopsies in a series of 
57 cases  [3]. Because the sextant biopsy technique has been 
increasingly replaced by multiple sampling methods, can-
cer detection rates on repeat biopsies following HGPIN 
have declined. Thus, repeat biopsy should be performed if 
HGPIN is detected by a sextant biopsy technique, and if the 
biopsy has been performed with multiple sampling, other 
parameters, such as PSA or rectal examination status, 
should be considered [1,9,10]. In the present study, pros-
tate cancer was not detected in any of the 40 patients with 
HGPIN. Recently, multiple sampling with laterally di-
rected systematic sextant biopsies has been shown to in-
crease the cancer detection rate by providing sufficient 
sampling in the first biopsy. There are direct and indirect 
findings indicating that such lesions are precancerous 
lesions. Thus, HGPIN appears to be a precancerous lesion 
of prostate cancer. As with prostate cancer, the prevalence 
of HGPIN also increases with age and represents a similar 
geographic/ethnic distribution. It is important to note that 
the detection of prostate cancer on repeat biopsies in pa-
tients with HGPIN detected in their first biopsies is not a 
missed diagnosis in the initial biopsy, but in fact might re-
flect the development of a new cancer arising from HGPIN 
[11]. The rate of prostate cancer diagnosis in a 3 year fol-
low-up among patients who were initially diagnosed as 
having HPIN was 25.8% in a small group studied by 
Lefkowitz et al [12].
It is known that needle biopsy does not provide clear find-
ings for the diagnosis of prostate cancer. Although the 
structural and cytological features of a small number of 
glands in a small focus may have atypical appearances on 
needle biopsy, such findings may be insufficient for the di-
agnosis of adenocarcinoma. The terms ASAP, focal glan-
dular atypia, atypical biopsy suspicious for malignancy, 
and borderline lesions are used in such conditions [13]. The 
term ASAP was coined by Iczkowski et al in 1997 [14]; how-
ever, it is not recommended by all pathologists. In a con-
sensus meeting in 2004 sponsored by the World Health 
Organization [15], the committee members recommended 
designating ASAP as either suspicious or highly suspicious 
for cancer. The reasons for this include the equation by 
some urologists of the term ASAP with HGPIN, and be-
cause all of the atypical foci are not always “small” acinar 
but may include glands with a larger diameter (such as a 
pseudohyperplastic pattern of cancer or adenocarcinoma 
with ductal features). Indeed, ASAP is a condition in which 
the pathologist has insufficient data to make diagnosis, 
and thus raises the suspicion of cancer. Therefore, a repeat 
biopsy should be performed in such cases. The cancer de-
tection rate on repeat biopsy is 21% to 51%, and a sub-
sequent biopsy should be directed to the locations in which 
ASAP was found in the initial biopsy, because a significant 
portion of the cancers are located in these regions [1,16]. 
In the present study, 38.2% of the patients shown to have 
ASAP in the initial biopsy were diagnosed with prostate 
cancer. Therefore, the high percentage of prostate cancer 
in patients with ASAP in the initial biopsies makes the 
need for aggressive follow-up reasonable.
The cancer detection rate declines with increasing pros-
tate volume. Levine et al reported that the cancer diagnosis 
rate was 43%, 27%, and 24% in men with prostate volumes 
less than 30 cc, between 30 cc and 50 cc, and greater than 
50 cc, respectively [17]. In second biopsies, two-fold higher 
positive results were obtained in patients with larger pros-
tate volumes. It is now accepted that the standard sextant 
biopsy technique does not provide adequate sampling. 
Hence, multiple sampling must be performed in patients 
with larger prostate volumes either in the initial or on re-
peat biopsies.
Although PSA is specific to prostate tissue, it is not specif-
ic to prostate cancer. The positive predictive value of serum 
PSA ＞4.0 ng/ml is reported to be 25% for prostate cancer 
[18]. When the cut off value is accepted to be 2.5 ng/ml, pros-
tate cancer detection rates increase, but the number of un-
necessary biopsies also increases [19]. Although the per-
cent free PSA maintains sensitivity for the early detection 
of prostate cancer, it also significantly improves the specif-
icity of PSA. A low percent free PSA indicates an increased 
risk of cancer; however, cancer is detected on biopsies of 
30% to 50% of men with percent free PSA levels ＜15% [20]. 
In the present study, we observed that the total PSA and 
the percent free PSA levels significantly increased the can-
cer detection rates in patients with ASAP in the initial 
biopsy. This condition is predictable for ASAP, which is as-
sociated with higher cancer detection rates on repeat 
biopsies.
A limitation of the present study was that the biopsy sam-
ples were not examined by the same pathologist, although 
all biopsies were examined in the same pathology 
laboratory. Furthermore, the retrospective design of the 
study and changes in PSA threshold level over time might 
have influenced the homogeneous distribution of the study 
population. In the present study, the PSA threshold value 
was 4.0 ng/ml in approximately one-half of the patients, 
whereas it was 2.5 ng/ml for the rest of the patients.
CONCLUSIONS
The diagnosis of ASAP is a strong risk factor for prostate 
cancer. A repeat biopsy should be performed for the entire 
prostate subsequent to the diagnosis of ASAP and the pa-
tients should be closely followed for the risk of cancer. If the 
initial biopsies are performed with multiple sampling, the 
final decision should be based on other parameters, such 
as PSA values and rectal examinations in patients with a 
biopsy result of HGPIN. We need to carefully follow-up 
such patients for their progression towards cancer in the 
future.
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